Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
P/E ratio for Viking Therapeutics, Inc. (VKTX)
P/E ratio as of 2023: -20.44
According to Viking Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -20.44. At the end of 2022 the company had a P/E ratio of -10.72.
P/E ratio history for Viking Therapeutics, Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -20.44 |
| 2022 | -10.72 |
| 2021 | -6.58 |
| 2020 | -11.34 |
| 2019 | -22.39 |
| 2018 | -19.96 |
| 2017 | -5.13 |
| 2016 | -1.31 |
| 2015 | -0.93 |
| 2014 | -1.58 |
| 2013 | -235.76 |
| 2012 | -26.70 |